Publications

Researchers identify Hepatocyte growth factor dependent signature may serve as a candidate predictive signature for patient enrollment in clinical trials using MET inhibitors.

Researchers find that activation of EGFR signaling leads to resistance of BRAF inhibitors, and that adding EGFR inhibitors increases the efficacy of BRAF inhibitor treatment.

Researchers used a next-generation shRNA platform to screen for genes conferring resistance to carfilzomib in multiple myeloma cells.

Researcehrs describe the discovery of the small-molecule probe BRD5631, and demonstrate that BRD5631 affects several cellular disease phenotypes previously linked to autophagy.

 The authors analyzed cellular perturbation profiles to identify established MoA proteins for 70% of tested compounds.

Researchers find that RAS pathway activation can act as a biomarker for sensitivity of ovarian cancer cells to decitabine.

Researchers report mTORC1 activation suppresses proliferation when cells rely on extracellular proteins as an amino acid source, and these results may have important implications for the use of mTOR inhibitors as therapeutics.

Researchers optimize several aspects of shRNA libraries to create next-generation high-complexity mouse and human shRNA libraries.

Researcehrs show human colorectal cancers (CRC)cells can revert to functioning normal cells given appropriate signals and provide compelling in vivo validation of the Wnt pathway as a therapeutic target for treatment of CRC.

Researchers introduce a cell culture medium that enables routine establishment of cell lines from human ovarian cancers which retain the genomic landscape, histopathology and molecular features of the original tumours.